Novartis Expects Zelnorm U.S. Approval Despite EU Filing Withdrawal
Executive Summary
Novartis continues to expect U.S. approval of Zelnorm (tegaserod) despite problems with the marketing application for the irritable bowel syndrome therapy in Europe.
You may also be interested in...
Solvay Cilansetron Irritable Bowel Safety Trial Size Reflects FDA Concerns
Solvay's proposed 1,000-patient pivotal safety trial for the irritable bowel syndrome drug cilansetron reflects FDA's concern about the size of the safety database for IBS therapies.
Solvay Cilansetron Irritable Bowel Safety Trial Size Reflects FDA Concerns
Solvay's proposed 1,000-patient pivotal safety trial for the irritable bowel syndrome drug cilansetron reflects FDA's concern about the size of the safety database for IBS therapies.
Novartis Starlix/Diovan Combo Trial In Diabetes Planned For Fourth Quarter
Novartis hopes to begin a study of Starlix and Diovan used in combination for the prevention of type 2 diabetes before year-end.